1. Home
  2. MVBF vs SLN Comparison

MVBF vs SLN Comparison

Compare MVBF & SLN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo MVB Financial Corp.

MVBF

MVB Financial Corp.

HOLD

Current Price

$28.07

Market Cap

329.1M

Sector

Finance

ML Signal

HOLD

Logo Silence Therapeutics Plc American Depository Share

SLN

Silence Therapeutics Plc American Depository Share

HOLD

Current Price

$4.75

Market Cap

318.4M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
MVBF
SLN
Founded
1997
1994
Country
United States
United Kingdom
Employees
N/A
N/A
Industry
Major Banks
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
329.1M
318.4M
IPO Year
N/A
N/A

Fundamental Metrics

Financial Performance
Metric
MVBF
SLN
Price
$28.07
$4.75
Analyst Decision
Strong Buy
Buy
Analyst Count
5
6
Target Price
$27.60
$39.67
AVG Volume (30 Days)
44.5K
339.8K
Earning Date
02-13-2026
02-26-2026
Dividend Yield
2.41%
N/A
EPS Growth
73.99
N/A
EPS
2.45
N/A
Revenue
$167,853,000.00
$25,830,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
$15.22
N/A
P/E Ratio
$11.54
N/A
Revenue Growth
18.75
40.39
52 Week Low
$15.59
$1.97
52 Week High
$28.96
$7.78

Technical Indicators

Market Signals
Indicator
MVBF
SLN
Relative Strength Index (RSI) 54.62 33.22
Support Level $26.70 $4.88
Resistance Level $28.84 $6.13
Average True Range (ATR) 0.84 0.49
MACD 0.11 -0.06
Stochastic Oscillator 70.98 7.27

Price Performance

Historical Comparison
MVBF
SLN

About MVBF MVB Financial Corp.

MVB Financial Corp is a bank holding company. The company provides Personal banking, Business banking, and Fintech solutions. The group has identified three reportable segments: CoRe Banking, Mortgage Banking, and Financial Holding Company. The majority of ts revenue generated from the CoRe Banking segment, which includes the Fintech division, represents banking products and services offered to customers by the Bank, loans, and deposit accounts. Revenue from banking activities consists of interest earned on loans and investment securities and service charges on deposit accounts.

About SLN Silence Therapeutics Plc American Depository Share

Silence Therapeutics PLC is a biotechnology company focused on discovering and developing novel molecules incorporating short-interfering ribonucleic acid or siRNA. Using its mRNAi GOLD platform, the company has generated siRNA product candidates both for internal development pipeline as well as for out-licensed programs with third-party collaborators. Its wholly owned pipeline is focused on three therapeutic areas: cardiovascular disease, hematology, and rare diseases. The different product candidates in its pipeline are Divesiran (SLN124), a siRNA product candidate that has the potential to treat several hematological disorders; Zerlasiran (SLN360), being developed as a potential treatment to reduce cardiovascular issues; SLN-312; SLN-548; and multiple other programs.

Share on Social Networks: